Tissue factor isoforms in cancer and coagulation: may the best isoform win.
Tissue factor (TF), the trigger of blood coagulation, is a 47 kDa membrane protein that also impacts on non-hemostatic processes, such as atherosclerosis, primary tumor growth and metastasis. TF binding to its ligand FVIIa induces activation of protease-activated receptor-2 and this event is thought to considerably influence atherosclerosis and tumor angiogenesis. TF-dependent activation of the coagulation cascade, rather than PAR-2 activation, then leads to the potentiation of metastasis. Importantly, a soluble alternatively spliced isoform of TF (asTF) has been discovered, but the function of asTF in hemostatic and non-hemostatic events is poorly understood. In this review, we aim to present a side-by-side evaluation of normally-spliced, full length TF (flTF) and asTF with regard to coagulant function, atherosclerosis, tumor progression and malignancy-associated thrombosis.
Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Centre, Leiden, The Netherlands.
Begüm
B
Kocatürk
Henri H
HH
Versteeg
D001777:Blood Coagulation / Q000187:drug effects*; D006490:Hemostatics / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy*; D020033:Protein Isoforms / Q000627:therapeutic use; D013925:Thromboplastin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D013927:Thrombosis / Q000175:diagnosis* / Q000209:etiology*; D016896:Treatment Outcome
D006490:Hemostatics; D020033:Protein Isoforms; D013925:Thromboplastin